Search Results

You are looking at 1 - 10 of 103 items for :

  • "high dose chemotherapy" x
Clear All
Full access

Rudolph M. Navari

therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement . Support Care Cancer 2005 ; 13 : 112 – 116 . 39. Rath U Upadhyaya BK Arechavala E . Role of ondansetron plus

Full access

Kim Margolin

. 5 Margolin KA . High-dose chemotherapy and stem cell support in the treatment of germ cell cancer . J Urol 2003 ; 169 : 1229 – 1233 . 6 Motzer RJ Bosl GJ . High-dose chemotherapy for resistant germ cell tumors: recent advances and

Full access

Matthias Holdhoff, Maciej M. Mrugala, Christian Grommes, Thomas J. Kaley, Lode J. Swinnen, Carlos Perez-Heydrich and Lakshmi Nayak

-MTX regimen. More aggressive, potentially more effective therapies have been investigated that include high-dose chemotherapy (HDC) with or without autologous stem cell transplant (ASCT); however, these regimens are limited to fitter, and often younger

Full access

Michael D. DeVita, Andrew M. Evens, Steven T. Rosen, Paul A. Greenberger and Adam M. Petrich

to high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT) at that time. She underwent consolidative radiation, during which she developed a scalp nodule and cervical lymphadenopathy, biopsy of which confirmed disease recurrence. She

Full access

Benjamin Levy, Ashish Saxena and Bryan J. Schneider

, maintenance chemotherapy, alternating combination chemotherapy regimens, and high-dose chemotherapy with growth factor support and/or hematopoietic stem cell rescue. 18 Although a handful of studies incorporating these strategies have shown a modest survival

Full access

Ayman Saad, Marcos de Lima, Sarah Anand, Vijaya Raj Bhatt, Ryan Bookout, George Chen, Daniel Couriel, Antonio Di Stasi, Areej El-Jawahri, Sergio Giralt, Jonathan Gutman, Vincent Ho, Mitchell Horwitz, Joe Hsu, Mark Juckett, Mohamed Kharfan Dabaja, Alison W. Loren, MSCE, Javier Meade, Marco Mielcarek, Jonathan Moreira, Ryotaro Nakamura, Yago Nieto, Julianna Roddy, Gowri Satyanarayana, Mark Schroeder, Carlyn Rose Tan, Dimitrios Tzachanis, Jennifer L. Burns and Lenora A. Pluchino

, 2 HCT is a potentially curative treatment option for patients with certain types of hematologic malignancies and is also used to support patients undergoing high-dose chemotherapy for the treatment of certain solid tumors. HCT is classified as

Full access

Agda Karina Eterovic, Ossama M. Maher, Joya Chandra, Ken Chen, Jason Huse and Wafik Zaky

medulloblastoma and, if the patient responded well, to follow with high-dose chemotherapy and autologous stem cell transplant (SCT) for curative intent. She was started on temozolomide (150 mg/m 2 x 5 days) and irinotecan (50 mg/m 2 x 5 days) every 28 days for 5

Full access

Ashraf Badros

Multiple myeloma is characterized by clinical and biologic heterogenicity. Recently, genetic analysis has provided predictable prognosis across different types of treatment. These advances have allowed patients to be categorized into different risk groups and have been particularly useful in defining a high-risk group with short survival after standard- and high-dose chemotherapies. Preliminary studies have shown promising outcomes after the use of novel agents, such as bortezomib, thalidomide, and lenalidomide in high-risk patients, including those eligible for autologous stem cell transplantation and those who cannot or will not undergo transplantation. The application of risk-based therapy and the potential of the new agents to abrogate the influence of adverse prognostic features may improve outcomes in these patients.

Full access

Morrow Gary R. PhD, MS 01 2007 5 5 1 1 44 44 50 50 0050044 10.6004/jnccn.2007.0006 Prevention of Emesis from Multiple-Day and High-Dose Chemotherapy Regimens Navari Rudolph M. MD, PhD 01 2007 5 5 1 1 51 51 59 59 0050051 10.6004/jnccn

Full access

Stephanie J. Lee

nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma . Blood 2003 ; 102 : 3447 – 3454 . 5 Child JA Morgan GJ Davies FE . High-dose chemotherapy with hematopoietic stem-cell rescue for